Tarsus Pharmaceuticals, Inc.·4

Nov 6, 4:40 PM ET

Lin Elizabeth Yeu 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Nov 6, 2024

Insider Transaction Report

Form 4
Period: 2024-11-04
Lin Elizabeth Yeu
Chief Medical Officer
Transactions
  • Award

    Stock Option (right to buy)

    2024-11-04+41,07441,074 total
    Exercise: $46.21Exp: 2034-11-03Common Stock (41,074 underlying)
  • Award

    Restricted Stock Units

    2024-11-04+27,27827,278 total
    Common Stock (27,278 underlying)
Footnotes (3)
  • [F1]Option granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.
  • [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
  • [F3]RSUs granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.

Documents

1 file
  • 4
    wk-form4_1730929222.xmlPrimary

    FORM 4